Clinical Trial Update: Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study [Phase 4]

View source ↗

Summary

Phase 4 multicenter real-world study evaluating the efficacy and safety of ensartinib as neoadjuvant therapy for stage IIA-IIIB ALK-positive non-small cell lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer
• Stage Iiib Non-small Cell Lung Cancer

Drugs mentioned

• Ensartinib (Ensartinib)

Snippet

Sponsor: Fujian Medical University Union Hospital | Conditions: ALK-positive Advanced NSCLC, ALK-positive Non-small Cell Lung Cancer (NSCLC) | Phase 4 | Status: NOT_YET_RECRUITING